#U.S. Healthcare Payer Analytics Market Share

[industrynewsupdates]

Future of U.S. Healthcare Payer Analytics Market: Insights from Industry Experts

The U.S. healthcare payer analytics market is expected to reach USD 19.4 billion by 2030, registering a CAGR of 22.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The digital advancements in the healthcare field, and the digitization of records, are one of the key factors driving the growth of this market. Adoption of such technologies is on an upward trend thus propelling the market. Digital data is being used to derive meaningful results, cost reduction, and minimize fraudulent insurance claims. 

The U.S. government has been increasingly spending on healthcare and focusing on improving digital infrastructure, which is boosting technological advancements in the field. Due to technological advancements, decision-making for payers and healthcare providers has become easier with the help of analytical tools. The overall increase in healthcare expenditure has amounted to more than USD 4 trillion in the year 2020. It is not only helping the healthcare industry develop faster but has also made healthcare more affordable and precise. 

The healthcare analytical tools are helping administrators and policymakers in determining what is the best course of action, how successful is it going to be, and how much cost can be saved by cutting unnecessary expenditures. For insurance companies, analytical tools have helped in recognizing patterns of insurance fraud and in turn saving billions of dollars per year. Doctors’ analytical tools have helped to determine the best treatment plans for a particular patient by studying and analyzing their history. 

In the analytics type, the descriptive analysis held the largest market share of 358% in 2022. Descriptive analytics has been widely used during COVID by various research organizations as well as laboratories, to determine how contagious the virus is by studying the past and present tests being conducted for coronavirus. Descriptive analytics analyzes data to derive meaningful results and can significantly impact future decisions. The fastest-growing was the predictive analytics segment, this helps in charting the best treatment plan for a personalized treatment plan, it can help the doctor to find out what works best for a patient and can give better treatment outcomes. 

Gather more insights about the market drivers, restrains and growth of the U.S. Healthcare Payer Analytics Market

U.S. Healthcare Payer Analytics Market Report Highlights

• The largest market share was held by descriptive analysis in the analytics type segment, it was used by laboratories and research organizations for studying the spread of the virus during the COVID outbreak

• The largest component was serviced, to cut down on costs incurred by training staff on healthcare analytics tools

• The on-premise delivery model had the largest share due to its ease of use and security of patient data; the cloud-based delivery model is gaining momentum due to its higher capacity

• The financial application segment has been the largest in 2022, due to its far-reaching implications in minimizing risks, identifying frauds in insurance claims, etc.

U.S. Healthcare Payer Analytics Market Segmentation

Grand View Research has segmented the U.S. healthcare payer analytics market based on analytics type, component, delivery model, and application: 

U.S. Healthcare Payer Analytics Analytics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Descriptive Analytics

• Predictive Analytics

• Prescriptive Analytics

U.S. Healthcare Payer Analytics Component Outlook (Revenue, USD Million, 2018 - 2030)

• Software

• Hardware

• Services

U.S. Healthcare Payer Analytics Delivery Model Outlook (Revenue, USD Million, 2018 - 2030)

• On–Premises

• Web-Hosted

• Cloud-Based

U.S. Healthcare Payer Analytics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Clinical

• Financial

• Operational & Administrative

Order a free sample PDF of the U.S. Healthcare Payer Analytics Market Intelligence Study, published by Grand View Research.

[market-research-report-arizton]

The Evolving Landscape of Pharmacy Benefit Management in the U.S.

The U.S. pharmacy benefit management market continues to transform the healthcare landscape, influencing how Americans access and afford prescription medications. With projections showing growth from $491.88 billion in 2023 to $680.73 billion by 2029 at a CAGR of 5.56%, this sector represents one of the most significant components of America's healthcare system.

Know More: https://www.arizton.com/market-reports/pharmacy-benefit-management-market-in-united-states

Market Drivers: Why PBMs Matter More Than Ever

Several factors are fueling the expansion of the U.S. pharmacy benefit management market. The aging baby boomer population, increasing healthcare expenditure, and rising prevalence of chronic conditions like heart disease have created greater demand for medication management services. Additionally, specialty pharmacies have experienced remarkable growth, as they provide comprehensive support services including medication management and patient education for those with complex conditions.

Pharmacy benefit trends indicate a move toward more innovative approaches as the industry adapts to changing healthcare needs. For instance, 58% of payers had entered outcomes-based contracts as of 2022, demonstrating the industry's shift toward value-based care models.

Regional Market Insights

The South dominates the U.S. pharmacy benefit management services market, accounting for over 29% of the market share in 2023. States like Kentucky, West Virginia, Virginia, and Louisiana have high percentages of insured residents, with approximately 90% of the total population covered by government or non-government insurance.

The Midwest region also holds a significant portion of the U.S. pharmacy benefit management market, with Michigan, Minnesota, Iowa, and Wisconsin leading in insurance coverage rates. Minnesota's Medical Assistance program serves as a prime example of comprehensive healthcare coverage in the region.

Emerging Pharmacy Benefit Trends

Innovative Pricing Strategies

One of the most notable pharmacy benefit trends is the evolution of pricing strategies. To counter high specialty drug prices, PBMs are increasingly adopting outcomes-based contracting models. This approach ties payment to the effectiveness of medications, potentially reducing costs while improving patient outcomes.

Another emerging trend involves advanced utilization management tools. By leveraging technology to optimize medication use, PBMs can identify cost-saving opportunities while enhancing patient care and adherence.

Real-Time Performance Optimization

Plan sponsors in the U.S. pharmacy benefit management market are seeking better understanding of PBM contracts while implementing new data analytics solutions. According to Milliman, identifying areas for improvement within PBM contracts can significantly reduce pharmacy program costs without altering members' benefits.

Real-time performance optimization represents one of the most transformative pharmacy benefit trends, as it enables more responsive and efficient management of prescription benefits. By incorporating AI and automation tools, PBMs can make more informed decisions and improve overall plan performance.

Market Segmentation

By Health Plan

Commercial health plans dominate the U.S. pharmacy benefit management market, with approximately 66% of Americans having commercial health insurance, primarily through employers. Preferred provider organizations (PPOs) remain the most common type of health plan.

However, Medicare plans represent the fastest-growing segment, driven by shifts toward virtual care delivery, increased home care options, and the adoption of value-based care models.

By Business Model

Insurance companies and retail pharmacies hold the largest share of the U.S. pharmacy benefit management services market. Major players like CVS Health, Walgreens Boots Alliance, Cigna, UnitedHealth Group, Walmart, Kroger, and Rite Aid accounted for 70% of U.S. prescription dispensing revenues in 2022.

Independent PBMs like MedImpact, Navitus, and PerformRx are also gaining ground as plan sponsors increasingly seek direct contracts to manage high drug costs.

By Service

Specialty pharmacy services represent the largest segment of the U.S. pharmacy benefit management market. This growth stems from new medications entering the pipeline, expanded treatment indications, and increasing chronic condition diagnoses.

Claims processing is projected to be the fastest-growing service segment, as plan sponsors recognize the importance of verifying accurate claims adjudication according to plan specifications and contractual agreements.

Key Market Players

The U.S. pharmacy benefit management market is dominated by several key players, including CVS Health, Cigna, UnitedHealth Group, Prime Therapeutics, MedImpact, and Humana Pharmacy Solutions. However, new entrants continue to challenge established companies, creating a more competitive landscape.

CVS Health stands out as a leader in the U.S. pharmacy benefit management services market, offering comprehensive healthcare and retail pharmacy services alongside PBM solutions, disease management services, and prescription drug plans.

Looking Ahead

As pharmacy benefit trends continue to evolve, the U.S. pharmacy benefit management market will likely face increased scrutiny and competition. Consumer pressure, political attention, legal challenges, and innovative new players are reshaping the industry landscape.

For stakeholders in this space, staying ahead of emerging pharmacy benefit trends and adapting to changing market conditions will be essential for success in this dynamic sector. Those who can leverage data analytics, embrace value-based care models, and improve patient outcomes will be well-positioned for growth in the expanding U.S. pharmacy benefit management market.

[meditechinsight01]

Global Healthcare MSO Market: The Role of AI and Automation in Strengthening 12% CAGR Growth by 2030

The Healthcare MSO (management service organization) Market is expected to grow at a CAGR of 12% by 2030. The growing trend of consolidation of smaller practices to achieve economies of scale and improve operational efficiency, rising aging population & chronic disease, growing demand for specialty care, increasing investments by private equity companies, and rising adoption of technology are some of the key factors driving the market.

A Healthcare Management Service Organization (MSO) is a health care specific company that provides non-clinical services (administrative and management services) to medical practices, healthcare providers, and ambulatory care facilities. Download a free sample report for in-depth market insight

Advantages Offered by MSOs Fuels Its Demand

MSO is beneficial to a health system in numerous ways:

Improved Quality and Better Efficiency: Due to a common governance structure care management delivery across the organization is standardized. Population health reporting and analytics member identification, risk stratification, attribution, care management delivery, and staffing are all streamlined, which in turn results in performance improvement and better utilization

Economies of Scale: MSOs urge the health systems to scout for partnerships, increase membership, and cut per-member-per-month (PMPM) management expenses by creating economies of scale

Network Expansion: MSOs offer a competitive edge to healthcare organizations as they relieve them from performing administrative and managerial responsibilities. MSOs serve as an incentive for health organizations that are looking to expand their network

"MSO ensures access to the lowest prices of medical supplies and services... MSOs aggregate volumes and hence are able to achieve economies of scale, which in turn allows them to obtain preferred pricing on medical supplies, healthcare insurance, etc."

CEO, Leading Healthcare MSO, U.S.

Foray of Next-Generation MSOs in Orthopedics – An Emerging Trend

Orthopedic physician practices often face challenges such as high overhead costs, deteriorating payments, increased regulatory requirements, and payer and administrative hurdles. On average, orthopedic physician practices spend ~ 50% of their revenue on overheads. To overcome these challenges, a new type of MSO has ventured into the market that not only provides orthopedic physician practices the tools they need to streamline business functions but also provides technical expertise to succeed.

For instance,

In June 2022, a coalition of leading independent orthopaedic and musculoskeletal (MSK) specialists announced the launch of MedVanta, the nation's largest physician-owned and operated musculoskeletal management services organization. MedVanta offers next-generation MSO strategies, people, processes, technology and solutions to independent orthopaedic and MSK practices for transforming business operations.

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold

The healthcare management service organization market is marked by the presence of both established and new players. Players operating in the market adopt both organic and inorganic growth strategies such as new product launches, and partnerships to garner market share. For instance,

In January 2025, Cority acquired Meddbase to enhance its occupational health offerings, aiming to improve employee outcomes and drive revenue growth for health service providers

In April 2023, TPG and AmerisourceBergen Corporation agreed to acquire OneOncology. OneOncology is one of the fastest-growing oncology MSOs in the United States

MSO Competitive Landscape

Some of the key players operating in the market include MedVanta, Envolve Health, One Oncology, Vanguard Health Solutions, Neolytix, Argusmso, Cority, HealthSmart Management Services Organization, Inc. and Conifer Health Solutions, LLC among others.

Unlock key data with a sample report for competitive analysis: https://meditechinsights.com/healthcare-mso-market/request-sample/

Global Healthcare Management Service Organization Market Segmentation

This report by Medi-Tech Insights provides the size of the global healthcare management service organization market at the regional- and country-level from 2023 to 2030. The report further segments the market based on services and ownership.

Market Size & Forecast (2023-2030), By Services, USD Million

Operations Management

Network Management

Quality Management

Care Management

Other Services

Market Size & Forecast (2023-2030), By Ownership, USD Million

Hospitals

Physician Groups

Investors

Others

Market Size & Forecast (2023-2030), By Region, USD Million

North America

US

Canada

Europe

UK

Germany

Italy

Spain

Rest of Europe

Asia Pacific

China

India

Japan

Rest of Asia Pacific

Latin America

Middle East & Africa

About Medi-Tech Insights Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde Associate, Medi-Tech Insights  +32 498 86 80 79  info@meditechinsights.com 

[global-research-report]

The Future of BPaaS in Healthcare Payers: Market Size, Trends, and Competitive Landscape in the U.S.

The U.S. business process as a service in healthcare payers market size is expected to reach USD 9.6 billion by 2030, registering a CAGR of 5.62% from 2024 to 2030, according to a new report by Grand View Research, Inc. Business process as a service (BPaaS) engagements contributed significantly to healthcare payer business process outsourcing revenue, and this percentage is likely to rise as the market for payer BPaaS expands due to the move toward value-based care, which has been hastened by COVID-19.

The adoption of BPaaS in the U.S. providers industry is growing quickly. Although providers have been around for a while, the Affordable Care Act made them more common and significant, which makes them well-suited to take advantage of BPaaS opportunity. The U.S. healthcare system is shifting from a fee-for-service to a value-based care model, which emphasizes quality of care and patient outcomes over volume of services provided. Growing pressure on the health system as a result of a constant increase in healthcare costs is contributing to rising penetration of value-based healthcare services in industry. BPaaS can help in delivering value-based care by providing healthcare organizations access to advanced analytics and data management tools.

The industry-specific regulatory compliances specify a range of compliance requirements for various industrial verticals. Health Insurance Portability and Accountability Act (HIPAA), Health Information Technology for Economic and Clinical Health (HITECH), and Payment Card Industry Data Security Standard (PCI DSS) are a few legislations that have impacted industry. In many instances, the market now supports compliance management as an administrative activity rather than a regulatory one. BPaaS providers could implement BPaaS solutions that can bridge compliance gaps between verticals and adapt to changes in existing regulations, leading to industry’s growth with a rise in adoption throughout the forecast period as all compliance adherence difficulties can be managed with their assistance.

U.S. Business Process As A Service In Healthcare Payers Market Report Highlights

Based on solution coverage, the market has been segmented into traditional and best-of-breed. Traditional BPaaS segment has accounted for the largest market share of over 75% in 2023, owing to lower cost of service and higher customer satisfaction

Based on buyer type, the government buyers segment held the majority of revenue share of over 73% in 2023. Government insurance companies have historically been main buyers for BPaaS due to modular implementations of medicaid management information systems (MMIS)

Small and medium-sized payers make up more than 70% of all payers in 2023 and have shown a stronger preference for the BPaaS model. In terms of plan types, medicare advantage and managed Medicaid have emerged as viable business cases, with MA accounting for a significant share percentage of the market

Based on value chain processes, administrative processes such as care managementhave seen the most BPaaS adoption. Payers are, however, progressively becoming aware of BPaaS's potential in processes such as claims management, population health management, and member engagement as well as in reducing medical expenses

U.S. Business Process As A Service In Healthcare Payers Market Segmentation

Grand View Research has segmented the U.S. business process as a service (BPaaS) in healthcare payers market based on solution coverage, buyer type, value chain processes, and buyer size:

U.S. BPaaS In Healthcare Payers Solution Coverage Outlook (Revenue, USD Billion, 2018 - 2030)

Traditional BPaaS

End-to-end Traditional BPaaS

Process-specific Traditional BPaaS

Best-of-breed BPaaS

End-to-end Best-of-breed BPaaS

Process-specific Best-of-breed BPaaS

U.S. BPaaS In Healthcare Payers Buyer Type Outlook (Revenue, USD Billion, 2018 - 2030)

Government Buyers

Medicare Advantage

Managed Medicaid

Commercial Buyers

Individual Health Plan

Employer-sponsored Health Plan

U.S. BPaaS In Healthcare Payers Value Chain Processes Outlook (Revenue, USD Billion, 2018 - 2030)

Claims Management

Member Engagement

Care Management

Others

U.S. BPaaS In Healthcare Payers Buyer Size Outlook (Revenue, USD Billion, 2018 - 2030)

Small Buyers

Midsized Buyers

Large Buyers

Key Players in the U.S. Business Process As A Service In Healthcare Payers Market

Accenture

Cognizant

HCL Technologies Limited

IBM

Infosys Limited

NTT DATA Corporation

Optum

TATA Consultancy Services Limited

UST

Wipro

EXL

Softheon, Inc.

Genpact

Change Healthcare

Firstsource

Celegence

Highmark Health

Order a free sample PDF of the U.S. Business Process As A Service In Healthcare Payers Market Intelligence Study, published by Grand View Research.

[deshpandeisha]

Transforming Patient Care: The Role of Predictive Analytics in Healthcare

The global healthcare predictive analytics arket size was USD 11.84 Billion in 2022 and is expected to register a rapid revenue CAGR of 24.7% during the forecast period. Rising demand for healthcare analytics, and rapid technological advancements in healthcare predictive analytics are key factors driving market revenue growth.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/2784

Competitive Terrain:

The global Healthcare Predictive Analytics industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Oracle, IBM, Verisk Analytics, Inc., MCKESSON CORPORATION, SAS Institute Inc., Inovalon, Veradigm LLC, Optum, Inc., MedeAnalytics, Inc., and CitiusTech Inc

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Healthcare Predictive Analytics market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Healthcare Predictive Analytics market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Healthcare Predictive Analytics market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/2784

Market Segmentations of the Healthcare Predictive Analytics Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Healthcare Predictive Analytics market on the basis of product, application, and region:

Segments Covered in this report are:

Component Outlook (Revenue, USD Billion; 2019-2032)

Software

Hardware

Application Outlook (Revenue, USD Billion; 2019-2032)

Financial

Operational

Clinical

End-Use Outlook (Revenue, USD Billion; 2019-2032)

Payer

Providers

Others

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/healthcare-predictive-analytics-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/2784

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report:  Ceramic Tiles Market | Life Science Analytics Market

[the-latest-research]

Real-world Evidence Solutions Market to be Worth $6.37 Billion by 2031

Meticulous Research®—a leading global market research company, published a research report titled,'Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS) End User - Global Forecast to 2031’.

The global RWE solutions market was valued at $2.62 billion in 2023. This market is expected to reach $6.37 billion by 2031 from an estimated $2.94 billion in 2024, at a CAGR of 11.7% during the forecast period of 2024-2031.

The increasing prevalence of chronic illnesses, drug development delays and the resulting rise in development costs, the growing emphasis on personalized healthcare, the move toward value-based care, and the expanding use of real-world evidence solutions in drug development and commercialization are the main factors propelling the growth of the real-world evidence solutions market. Moreover, participants in the real-world evidence solutions market could expect to see substantial development prospects due to the emergence of emerging economies and the growing emphasis on end-to-end RWE services. Many organizations use delivery methods that can offer value-based care with the goal of improving population health and achieving better results. An end-to-end strategy for utilizing a life sciences organization's data, evidence, and knowledge assets enables R&D to commercialization through insight-driven decision-making.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=4954

Key Players

The key players operating in the global real-world evidence solutions market are IQVIA Holdings Inc. (U.S.), Elevance Health, Inc. (U.S.), ICON plc (Ireland), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Revvity, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Oracle Corporation (U.S.), SAS Institute Inc. (U.S.), Parexel International Corporation (U.S.), and HealthVerity, Inc. (U.S.).

Real-world Evidence Solutions Market: Future Outlook

The global RWE solutions market is segmented by Component (Datasets [Disparate Datasets {EMR/HER/Clinical Data, Claims & Billing Data, Pharmacy Data, Product/Disease Registries Data, Genomics Data, and Other Disparate Datasets}, and Integrated Datasets], and Consulting & Analytics), Application (Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals [Oncology, Neurology, Immunology, Cardiovascular Diseases, and Other Therapeutic Areas], Medical Device Development & Approvals, Post-market Surveillance, and Other Applications), End User (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Other End Users), and Geography. This study also evaluates industry competitors and analyzes the market at the global and regional levels.

Among all the components studied in this report, in 2024, the datasets segment is expected to account for the largest share of 53% of the RWE solutions market. The significant market share of this segment can be attributed to several factors, including the growing amount of medical data generated by hospitals, the growing reliance on outcome-based research on real-world data (RWD), and the growing healthcare payer, regulatory, and provider demand for drug safety information.

Among all the applications studied in this report, the drug development & approvals segment is projected to witness the highest growth rate of 13.1% during the forecast period of 2024–2031. The pharmaceutical and biopharmaceutical industries have been forced to concentrate on medication development due to the increasing prevalence of diseases, which has fueled the market's expansion. All parties involved can benefit from RWE's assistance in responding to these developments. By facilitating drug approvals, quickening the pace of development, and assisting in the analysis of the effects of novel medicines, the efficient application of RWE can propel the market's expansion.

Among all the end users studied in this report in 2024, the pharmaceutical, biotechnology, and medical device companies segment is expected to account for the largest share of 39.1% of the RWE solutions market. The largest portion of the market is accounted for by pharmaceutical and biotechnology businesses, which are using RWE more and more to gather real-time post-trial data about medications. Researchers and healthcare professionals can better comprehend and manage medication errors, side effects, and drug responses with the aid of the RWE drug information. Furthermore, the life sciences sector is utilizing RWE solutions at a quick pace to perform observational research, expedite medication development, and find qualified candidates for marketing campaigns and clinical trials.

This research report analyzes major geographies and provides a comprehensive analysis of the market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Taiwan, Singapore, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa.

Among all the regions studied in this report, in 2024, the North America region is expected to account for the largest share of 48.9% of the RWE solutions market. The pharmaceutical and biotechnology industries' rising R&D spending, the existence of significant market participants, government measures that are supportive, the adoption of EHR in hospitals, and strict drug approval procedures are all responsible for this region's substantial market share.

Complete Report  Here : https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954

Key questions answered in the report-

Which are the high-growth market segments in terms of component, application, end user, and region/country?

What was the historical market size for the RWE solutions market globally?

What are the market forecasts and estimates for the period 2024–2031?

What are the major drivers, restraints, challenges, opportunities, and trends in the global RWE solutions market?

Who are the major players in the global RWE solutions market?

What is the competitive landscape like, and who are the market leaders in the global RWE solutions market?

What are the recent developments in the global RWE solutions market?

What are the different strategies adopted by the key players in the global RWE solutions market?

What are the geographical trends and high-growth regions/countries?

Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

[savibangar]

Detailed Analysis of the RWE Oncology Market Report by Meticulous Research®

Meticulous Research®, recognized for its expertise in market analysis, has published a pivotal report titled, “RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), End User (Pharma, Payer, Provider) - Global Forecast to 2029.” This report provides an extensive overview of the real-world evidence (RWE) oncology solutions market, highlighting significant growth prospects.

The report forecasts a robust CAGR of 14.2% from 2022 to 2029, predicting the market will reach $1.65 billion by the end of this period. This growth trajectory is attributed to the escalating incidence of cancer globally, the surge in healthcare big data, a transition toward value-based care models, and an increasing focus on personalized medicine. However, the report also notes that the absence of standardized methodologies for RWE development poses a considerable challenge to market expansion.

Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5276

The RWE oncology solutions market is categorized into components, applications, and end users, with a thorough analysis provided for each segment. In 2022, the real-world datasets component is expected to dominate the market. The proliferation of medical data generated in healthcare facilities, alongside the growing reliance on outcome-focused studies, underpins the importance of this segment. Additionally, there is an increasing demand for data that informs drug safety from various stakeholders, including payers and regulators.

In terms of applications, the drug development and approvals segment is projected to lead the market. The incorporation of quality-of-life metrics and Patient-Reported Outcome Measures (PROMs) into clinical trials reflects the shift toward patient-centered approaches in oncology. RWE plays a crucial role in elucidating disease trajectories and treatment pathways, which is especially critical given the rising cancer rates. The ability to leverage real-world data can significantly enhance drug discovery processes, streamline regulatory approvals, and provide insights into the effectiveness of new oncology treatments.

Browse in Depth: https://www.meticulousresearch.com/product/rwe-oncology-market-5276

When examining end users, pharmaceutical and medical device companies are anticipated to command the largest share of the market. This dominance is driven by the essential role of RWE in cancer drug development and the ongoing need to evaluate drugs' real-world performance. As the industry moves towards a value-based care paradigm, pharmaceutical companies are increasingly utilizing RWE to glean insights into clinical practices and health outcomes, thus improving cancer care delivery.

The report also conducts a geographical analysis, providing insights into key markets across North America (including the U.S. and Canada), Asia-Pacific (featuring Japan, China, and India), Europe (comprising Germany, France, the U.K., among others), Latin America, and the Middle East & Africa. This regional focus offers a comprehensive understanding of market dynamics and growth opportunities within the RWE oncology solutions landscape as it approaches 2029.

Request for Customization Report: https://www.meticulousresearch.com/request-customization/cp_id=5276

Related Research Reports:

Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis >> https://www.meticulousresearch.com/product/Real-World-Evidence-Solutions-Market-4954

Synthetic Biology Market Size, Share, Forecast, & Trends Analysis>> https://www.meticulousresearch.com/product/synthetic-biology-market-5826

Bioinformatics Market Size, Share, Forecast, & Trends Analysis >> https://www.meticulousresearch.com/product/bioinformatics-market-5731

Spatial Genomics Market >> https://www.meticulousresearch.com/product/spatial-genomics-market-5763

RWE Oncology Market >> https://www.meticulousresearch.com/product/rwe-oncology-market-5276

Negative Pressure Wound Therapy (NPWT) Market >> https://www.meticulousresearch.com/product/negative-pressure-wound-therapy-market-5535

U.S. Real-World Evidence (RWE) Solutions Market >> https://www.meticulousresearch.com/product/us-rwe-solutions-market-5243

[tamanna31]

U.S. Management Service Organization Market to register high demand rate by 2030

U.S. Management Service Organization Industry Overview

The U.S. management service organization market size was estimated at USD 46.78 billion in 2023 and is expected to grow at a CAGR of 12.96% from 2024 to 2030. The U.S. MSO market is expected to grow significantly, driven by the rise in investments by private equity firms, and the increasing consolidation of smaller practices. The rising focus on value-based care is attributed to several factors such as the shift toward value-based care models, which prioritize quality and outcomes over volume. This has prompted MSOs to adapt their services to meet the changing needs of healthcare providers and payers.

The growing demand for the expansion of service networks by health systems is leading to a rise in investments by private equity companies. Such investments enable organizations to provide quality clinical care without the burden of administrative and management functions. For instance, in April 2023, AmerisourceBergen Corporation and Tarrant Capital IP, LLC, an alternative asset management provider, acquired OneOncology, a network of oncology practices, from General Atlantic Service Company, L.P. This acquisition aims to strengthen AmerisourceBergen Corporation's relationships with community oncologists and expand on solutions in the specialty as well as build a platform in partnership with Tarrant Capital IP, LLC. Such investments and growing acquisitions by private equity firms are expected to drive the market in the coming years.

Gather more insights about the market drivers, restrains and growth of the U.S. Management Service Organization Market

The growing availability of data and advancements in technology have enabled MSOs to better track and measure performance, identify areas for improvement, and implement evidence-based practices. Management service organizations are leveraging sophisticated IT infrastructure and analytics to categorize patients, determine best practices, and drive quality improvement initiatives. For instance, in November 2023, Apollo Medical Holdings, Inc. partnered with Wider Circle, a community health organization, to provide enhanced care management to Medicaid members across California. The partnership aimed to deliver high-quality, value-based care to all community members. The increasing emphasis on population health management and care coordination has propelled MSOs to focus on value-based care.

The emergence of next-generation MSOs in the U.S. brings new opportunities due to the shift of traditional practice management services and a broad range of administrative support services to physician practices. There has been a rise in private equity partnerships, and private practice physicians are investing and joining MSOs to achieve operational efficiency, removing administrative burdens while maintaining clinical autonomy. For instance, in October 2023, Ascend Capital Partners acquired a majority share of Seoul Medical Group (SMG). This acquisition aims to create premier community-focused healthcare companies equipped to manage Medicaid and Medicare patient populations. Such factors create opportunities for the growth of the market in the coming years.

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global surgical drills market size was estimated at USD 1.27 billion in 2023 and is projected to grow at a CAGR of 5.5% from 2024 to 2030. 

The global oral appliances market size was estimated at USD 908.7 million in 2023 and is expected to grow at a CAGR of 5.72% from 2024 to 2030.

Key U.S. Management Service Organization Company Insights

The demand for advanced MSO services has led to increased competition among companies in the U.S. Management Service Organization (MSO) market. Some of the emerging companies include Vanguard Health Solutions, Advanced Medical Management, and HealthSmart Management Services Organization, Inc.

Key U.S. Management Service Organization Companies:

Conifer Health Solutions, LLC. (TH Medical)

Network Medical Management (Apollo Medical Holdings, Inc.)

MedPOINT Management, Inc.

Vanguard Health Solutions

Prospect Medical Holdings, Inc.

Centene Corporation

Advanced Medical Management

HealthSmart Management Services Organization, Inc.

Pacific Partners Management Services Inc., a division of HCA Healthcare

MSO Inc. (Southern California)

Recent Developments

In January 2024, Apollo Medical Holdings, Inc. established a long-term strategic partnership with BASS Medical Group, a multispecialty medical group. The partnership aims to provide high-quality care through value-based arrangements to patients with various types of insurance, including Medicaid, Medicare, ACA Marketplace, and commercial.

In October 2023, Seoul Medical Group (SMG) acquired Advanced Medical Management, which provides comprehensive administrative support to physicians, including claims processing, quality training, and credentialing.

In May 2023, Conifer Health Solutions, LLC entered into a new partnership with Northwest Community Healthcare. With this partnership, the company was expected to continue to provide its expertise in RCM services to Northwest Community Healthcare.

In May 2023, Centene Corporation's Medicare brand, Wellcare, launched a preferred Medicare sales and distribution partnership program to improve quality and customer experience, strengthening sales partnerships.

Order a free sample PDF of the U.S. Management Service Organization Market Study, published by Grand View Research.

[chemanalystdata]

Terbinafine Hydrochloride Prices Trend, Monitor, News, Analytics and Forecast | ChemAnalyst

Terbinafine Hydrochloride Prices: During the Quarter Ending December 2023

Terbinafine Hydrochloride, a pharmaceutical compound primarily used to treat fungal infections of the skin and nails, holds significant importance in the healthcare industry. Understanding the dynamics of terbinafine hydrochloride prices is essential for stakeholders including pharmaceutical manufacturers, healthcare providers, and consumers. The pricing of terbinafine hydrochloride is influenced by various factors, with supply-demand dynamics playing a pivotal role. As a key ingredient in antifungal medications, terbinafine hydrochloride demand fluctuates based on factors such as the prevalence of fungal infections, prescribing patterns by healthcare professionals, and patient preferences. Changes in these demand drivers can impact pricing, with increased demand typically leading to higher prices and vice versa.

Moreover, the cost of production significantly affects terbinafine hydrochloride prices. Pharmaceutical manufacturing involves complex processes, stringent quality control measures, and compliance with regulatory standards, all of which contribute to production costs. Factors such as raw material prices, labor wages, energy costs, and manufacturing technologies influence the overall cost structure for terbinafine hydrochloride manufacturers, thereby impacting pricing decisions. Additionally, research and development (R&D) investments in drug discovery, formulation optimization, and process innovation can influence production costs and subsequently affect pricing strategies.

Furthermore, regulatory factors play a crucial role in shaping terbinafine hydrochloride prices. Pharmaceutical products are subject to stringent regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe. Compliance with regulatory requirements, including clinical trials, drug approvals, and post-market surveillance, incurs costs for manufacturers, which may be reflected in product pricing. Additionally, changes in regulatory policies, such as patent expirations, generic drug approvals, or drug reclassifications, can impact market dynamics and pricing competitiveness.

Get Real Time Prices of Terbinafine Hydrochloride: https://www.chemanalyst.com/Pricing-data/terbinafine-hydrochloride-1461

Global market dynamics and competition also influence terbinafine hydrochloride prices. The pharmaceutical industry operates in a competitive environment characterized by multiple manufacturers, generic alternatives, and international trade. Price competition among manufacturers vying for market share can lead to price fluctuations and margin pressures. Additionally, market consolidation, mergers, and acquisitions within the pharmaceutical sector can impact pricing strategies and market dynamics, influencing terbinafine hydrochloride prices.

Furthermore, macroeconomic factors such as currency exchange rates, inflation rates, and economic conditions can influence terbinafine hydrochloride prices. Currency fluctuations affect the cost of imported raw materials and finished products, impacting pricing for both manufacturers and consumers. Economic downturns or recessions may lead to changes in healthcare spending patterns, affecting demand for pharmaceutical products like terbinafine hydrochloride and influencing pricing dynamics.

Lastly, healthcare insurance coverage and reimbursement policies impact terbinafine hydrochloride prices, particularly in markets with significant reliance on third-party payers. Formulary restrictions, co-payments, and insurance coverage decisions influence patient access to terbinafine hydrochloride medications and can affect demand and pricing. Additionally, pricing negotiations between pharmaceutical manufacturers and payers, such as government agencies, insurance companies, and pharmacy benefit managers, play a role in determining market prices for terbinafine hydrochloride products.

In conclusion, terbinafine hydrochloride prices are influenced by a multitude of factors spanning supply-demand dynamics, production costs, regulatory considerations, global market dynamics, and macroeconomic factors. Stakeholders in the pharmaceutical industry must navigate these complexities, leveraging market insights and strategic pricing approaches to optimize pricing strategies and ensure accessibility of terbinafine hydrochloride medications for patients in need. By understanding the multifaceted nature of terbinafine hydrochloride pricing, stakeholders can make informed decisions to support sustainable growth and innovation in the pharmaceutical sector.

Get Real Time Prices of Terbinafine Hydrochloride: https://www.chemanalyst.com/Pricing-data/terbinafine-hydrochloride-1461

Contact Us:

ChemAnalyst

GmbH - S-01, 2.floor, Subbelrather Straße,

15a Cologne, 50823, Germany

Call: +49-221-6505-8833

Email: sales@chemanalyst.com

Website: https://www.chemanalyst.com

[bridgestonehrs]

INEVITABLE EFFECT OF COVID -19 ON WORLD AND DENIALS MANAGEMENT SOFTWARE

The System International unites is currently near to a crisis. Knowledge analysis shows that a next crisis is going to be reached in 2020, and or minus 2 years; presumptuous that the model that's used is correct. In these cases, a crucial state of the system that followed these crucial points went hand in hand with a general war. These general wars were instrumental within the reorganization of the international order to produce one more amount of relative stability Denial management software. The last general war (World War II, 1939-1945) has resulted within the world organization international order. However, a primary international war cycle conjointly started in 1945, with the implementation of this new international order.

That is however the political orientation system works linear unit develops; high-powered by tensions caused by increment, and rivalries between states. Analysis shows that 2020 may well be the crisis of this latest cycle. If history repeats itself – and there's each reason to expect this – then a general war ensues, transportation a couple of new and ‘upgraded’ international order: a world organization two.0, thus to talk. Typically, the amount between the tipping purpose of a war cycle (2011 during this case) and also the crisis is characterised by the build-up of tensions and political and social volatility: The international order isn't any longer ready to properly regulate these tensions. This behaviour has been visible since 2011, and currently the corona virus pandemic comes on high of this volatility.

The injury of this pandemic is nice in itself, however it's not restricted to health risks; economies of all countries, and also the world economy also are receiving new blows. There is no international cooperation to combat the pandemic, on the contrary: The saying is “everybody for him- or herself”, not only if it considerations toilet tissue, Healthcare Denial Management Softwarehowever conjointly once it's concerning medical providers and whole economies, for instance. Borders are closed too, not solely to prevent the unfold of the virus – that is an obvious live in some cases – however out of reflex, to make sure a false feeling of security and management. International cooperation is essential to (eventual) success: while not international cooperation, there'll be additional injury, and a (much) longer amount of recovery. The U.S and China place the pandemic and its consequences within the context of their mutual rivalries, and it provides fertile soil to any enlarge variations in interests and variations between political systems. China has managed to bend the pandemic that started in China, to its own advantage, it seems. The U.S, which is additionally scuffling with dysfunctional internal politics, is failing for itself and internationally. The U.S is anticipated to be hit onerous by the pandemic, as well as economically and politically.

A number of recent trends within the health care market have escalated the pressing issue of hospital denial management. Hospitals ar troubled to gather each dollar they're owed, and every of those new developments poses another threat.

1. Demand quality is on the increase. Insurance firms are adding progressively advanced needs into contracts with suppliers. Organizations are seeing up to twenty % of claims come with initial denial. Meaning suppliers ought to work, or appeal, one out of each 5 claims. This constant work distracts from care and inhibits revenue cycle improvement initiatives.

2. Patient responsibility is increasing. Insurers and employers are put additional pressure on the patient, via high deductible health plans and different strategies, to share the responsibility of the payment. From 2011 to 2016, of yank adults listed in high deductible health plans exaggerated virtually fifty present, increasing patient payment parts, that are typically tougher to gather in an exceedingly timely manner than industrial or government payer parts. Denials hindrance and backbone programs to maximise insurance collections are escalating in necessity so as attain revenue cycle vitality.

3. Margin pressures thanks to value-based initiatives are a risk to revenue cycles and have an effect on overall gain. While value-based care has positive implications for potency and price savings semi-permanent, it conjointly means that sure service lines might not be as profitable as they traditionally were, ensuing from efforts to standardize value and payments. It's imperative that hospitals cut back their overall overhead, as well as prices related to their denials management initiatives.

4. Non-current denials management software package. According to a HIMSS Analytics 2016 survey, just about third of health care suppliers still use a manual claim denials management method. Hospitals are slow to adopt denials management software package, and plenty of still accept noncurrent paper-based processes or databases they'll have developed in-house, however that lack the automation and call support to assist optimize denials management. Regulatory changes are planning to persist; these issues can still plague hospital denials management. However the proper denials management resolution – a mix of service and technology – will address problems before they become unmanageable.

[industrynewsupdates]

Exploring Healthcare Digital Experience Platform Market: Trends and Future Outlook

The global healthcare digital experience platform market size is expected to reach at USD 2.9 billion in 2030 and is forecasted to grow at a CAGR of 12.5% from 2024 to 2030. The increase in the adoption of healthcare digital experience platforms for improving connectivity and growing requirements to curb costs in healthcare settings are key factors contributing to the market growth. Features such as end-to-end efficiency accelerating customer acquisition, boosting retention period, and promoting long-term growth prospects among various payer organizations in the healthcare sector are among other key driving factors.

The healthcare digital experience platform combines various key digital technologies, such as content management systems, analytics, patient data, and AI, along with marketing automation capabilities that aid patients with real-time personalized content through a single platform for enhanced patient engagement. Continuous technological upgrades for optimizing healthcare digital experiences with the advent of native analytics and machine learning capabilities are driving the market. In addition, the growing focus of the healthcare sector on improving patient engagement and interaction, adopting a patient-centric marketing approach, and providing customized solutions is expected to accelerate the deployment of these platforms across the sector.

Furthermore, an increasing number of digital experience platform offerings in the healthcare market are leveraging various advanced technologies, including AI and machine language. In addition, several IT vendors and healthcare organizations are setting up partnerships and collaborations to curb rising costs and establish connected digital experiences. The payers and providers shortly are anticipated to adopt these platforms at faster rates to meet the growing patient demand for enhanced care.

Gather more insights about the market drivers, restrains and growth of the Healthcare Digital Experience Platform Market

Healthcare Digital Experience Platform Market Report Highlights

• The market growth can be attributed to an increase in the number of government initiatives worldwide to promote digitalization

• The platform component segment dominated the global market in 2023 due to the growing adoption of digital experience platforms by various startups and organizations

• The cloud-based delivery mode segment held the largest revenue share during forcast period owing to the growing demand for cloud technology across different organizations for secure information sharing, streamlining costs, and improving operational efficiency

Healthcare Digital Experience Platform Market Segmentation

Grand View Research has segmented the global healthcare digital experience platform market report on the basis of component, delivery mode, application, and region:

Healthcare Digital Experience Platform Component Outlook (Revenue, USD Million, 2020 - 2030)

• Platform

• Services

Healthcare Digital Experience Platform Delivery Mode Outlook (Revenue, USD Million, 2020 - 2030)

• On-premises

• Cloud Based

Healthcare Digital Experience Platform Application Outlook (Revenue, USD Million, 2020 - 2030)

• Business-to-Consumer (B2C)

• Business-to-Business (B2B)

• Others

Healthcare Digital Experience Platform Regional Outlook (Revenue, USD Million, 2020 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o South Korea

o Thailand

• Latin America

o Brazil

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

o Kuwait

List of Key Players in Healthcare Digital Experience Platform Market

• Accenture

• Sitecore

• Optimizely

• Liferay Inc.

• Wipro

• Cognizant

• SoftServe Inc.

• Oracle

• Microsoft

• Salesforce, Inc.

• Open Text Corporation

Order a free sample PDF of the Healthcare Digital Experience Platform Market Intelligence Study, published by Grand View Research.

[marketresearchlove-blog]

Multiplex Assays Market is Driven by Increasing Awareness About Multi factorial Nature of Various Diseases

Multiplex Assays Market Scenario

According to Data Bridge Market Research the multiplex assays market is attaining a significant growth in developing economies during the forecast period of 2019-2026 due to factors such as increasing usage in companion diagnostics, prevalence of benefits associated with singleplex over traditional assays and surging number of application which will help in boosting the growth of the market.

Now the question is which are the other regions that multiplex assays market is targeting? Data Bridge Market Research has estimated a large growth in Asia-Pacific multiplex assays market and the market leaders targeting China, India and Japan to be their next revenue pockets for 2020. The Data bridge market research new reports highlight the major growth factors and opportunities in the multiplex assays market.

Request-a-sample@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=-multiplex-assays-market

Multiplex Assays Market Development in 2019

·         In July 2019, Bio-Rad Laboratories, Inc. launched Bio-Plex Pro Human Immunotherapy Panel 20-plex, which helps in communicating within the immune system while provides a vital role in various diseases such as cancer and other auto immune diseases.  

Scope of the Multiplex Assays Market

Multiplex assays market is segmented on the basis of countries into U.S., Canada, Mexico in North America, Brazil, Argentina, Rest of South America as a part of South America, Germany, France, U.K., Italy, Spain, Netherlands, Belgium, Russia, Turkey, Switzerland, Rest of Europe in Europe, China, Japan, India, Australia, Singapore, Thailand, Malaysia, South Korea, Indonesia, Philippines, Rest of Asia-Pacific (APAC) as a part of Asia-Pacific (APAC), U.A.E, Egypt, Saudi Arabia, South Africa, Israel,  Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

·         All country based analysis of the multiplex assays market is further analyzed based on maximum granularity into further segmentation. On the basis of products and services, the market is segmented into reagents & consumables, instruments & accessories, software & services.

·         Based on type, the market is segmented into nucleic acid multiplex assays, protein multiplex assays, cell-based multiplex assays. Based on technology, the market is segmented into protein microarray, polymerase chain reaction, multiplex real-time PCR, flow cytometry, fluorescence detection, luminescence, others.

·         Based on end-user, the market is segmented into hospitals, clinical laboratories, pharmaceutical & biotechnology companies, research institutes, others. The applications covered for the report are clinical diagnostics, research & development.

·         Multiplex assays are a kind of immunoassay used in the determination of multiple analyte in a single sample by using magnetic or non-magnetic beads. Due to the rising research activities, multiple assays will provide various benefits in clinical diagnostics.   

Key Pointers Covered in the Multiplex Assays Market Industry Trends and Forecast to 2026

·         Market Size

·         Market New Sales Volumes

·         Market Replacement Sales Volumes

·         Market Installed Base

·         Market By Brands

·         Market Procedure Volumes

·         Market Product Price Analysis

·         Market Healthcare Outcomes

·         Market Cost of Care Analysis

·         Market Regulatory Framework and Changes

·         Market Prices and Reimbursement Analysis

·         Market Shares in Different Regions

·         Recent Developments for Market Competitors

·         Market Upcoming Applications

·         Market Innovators Study

Key Market Competitors Covered in the report

·         BD

·         Bio-Rad Laboratories, Inc.

·         Thermo Fisher Scientific Inc.

·         F. Hoffmann-La Roche Ltd

·         Cepheid

·         Siemens AG

·         Hologic Inc.

·         Luminex Corporation.

·         MESO SCALE DIAGNOSTICS, LLC.

·         QIAGEN

·         PerkinElmer Inc.

·         Illumina, Inc.

·         AGENA BIOSCIENCE, INC.

·         Olink

·         Randox Laboratories Ltd.

·         Bio-Techne.

·         Agilent Technologies

·         Sysmex Corporation

Request for Toc@ https://www.databridgemarketresearch.com/toc?dbmr=-multiplex-assays-market

Multiplex Assays MarketMarket Size, Status and Forecast 2018 – 2025

1 Market Overview

2 Manufacturers Profiles            

3  Multiplex Assays MarketSales, Revenue, Market Share and Competition by Manufacturer

4  Multiplex Assays MarketMarket Analysis by Regions

5 North America Multiplex Assays Marketby Countries

6 Europe Multiplex Assays Marketby Countries

7 Asia-Pacific Multiplex Assays Marketby Countries

8 South America Multiplex Assays Marketby Countries

9 Middle East and Africa Multiplex Assays Marketby Countries

10  Multiplex Assays MarketMarket Segment by Type

11  Multiplex Assays MarketMarket Segment by Application

12 Multiplex Assays MarketMarket Forecast

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendixes

 Research Methodology:  Multiplex Assays Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement,  versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

·         Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

·         Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Related Reports

Loan Servicing Software Market

North America Container Security Market

Walnut Milk Market

[healthcaremarketfmi]

Healthcare Cloud Infrastructure Market Top Players with Share, Product Scope, Total Revenues, Business Development and Opportunities till 2033

The Healthcare Cloud Infrastructure Market is expected to register a valuation of US$ 464.1 Bn by 2033 at a CAGR of 23.9%, according to a recently published Future Market Insights report. The market through healthcare cloud infrastructure services is projected to grow at a CAGR of 23.7% from 2023 to 2033.

The market is growing rapidly due to a significant surge in digitalization, artificial intelligence, and machine learning computing, rising cloud database infrastructure, and increasing capital expenditure. The efficient cloud database management system enhances the quality of treatment and care of individuals.

The adoption of data analytics, wearable devices, and the Internet of Things surges the demand for the healthcare cloud computing market. The Internet of Things in Healthcare Industry is expected to change the dynamics of the healthcare industry. Cloud infrastructure helps to collect information on individual and remote monitoring of patients in the healthcare industry.

Increased use of IoT solutions in healthcare is anticipated to spur market expansion over the forecast period. Market players including IBM, SAP SE, and Cisco Systems Inc. are leveraging IoT technologies and solutions to enhance healthcare products and services throughout their transactional activities.

Cloud computing allows access to the patient data to the manufacturer of the devices, services providers, doctors, and the patient as well. Cloud systems are integrated with healthcare organizations and represent a privacy and security safeguard for healthcare data by encrypting it with data hard forking and fine-grained access controls.

The market in North America is expected to cross US$ 150 Billion by 2023, growing at a CAGR of over 20% from 2023 to 2033. The healthcare IT expenditure in the regions has been skyrocketing. The number of remote patient monitoring in the U.S. increased from 39.3 Million in 2021 to 45.1 Million in 2022. By 2025, this number is expected to swell to 70.6 Million. Besides, telemedicine appointments in the region have also surged which has consequently triggered the demand for healthcare cloud infrastructure in the region.

Competitive Landscape

The key players operating in the global healthcare cloud infrastructure market are Dell, Hewlett-Packard Enterprise Development LP, Microsoft, Oracle Corporation, and IBM.

A few of the recent developments in the Healthcare Cloud Infrastructure Market are:

In February 2022, IBM and SAP strengthened their partnership to enable clients to move their workloads from SAP solutions to the Cloud.

In February 2022, Kyndryl partnered with AWS to accelerate cloud adoption and innovation for customers.

In July 2021, Amazon announced the rollout of AWS for Health cloud services for healthcare, genomics, and biopharma.

In July 2021, Wellforce announced the migration of its Epic infrastructure to AWS cloud.

For More Information: https://www.futuremarketinsights.com/reports/healthcare-cloud-infrastructure-market

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Healthcare Cloud Infrastructure market, presenting historical market data (2018-2022) and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of Components (Hardware, Services) and End-User (Healthcare Payers, Healthcare Providers) across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Market Segments Covered in Healthcare Cloud Infrastructure Market Analysis

By Component:

Hardware

Server

Storage

Network

Services

Software-as-a-service (SaaS)

Infrastructure-as-a-service (IaaS)

Platform-as-a-Service (PaaS)

By End-Use:

Healthcare Payers

Healthcare Providers

[adityarana1687-blog]

Population Health Management Market Is Expected To Witness Higher Demands Till 2030

The global population health management market size is expected to reach USD 280.8 billion by 2030, registering a CAGR of 21.9% over the forecast period, according to a new report by Grand View Research, Inc. The need for population health services that combine multiple functionalities is increasing due to the complex nature of care delivery and payment models. Population Health Management (PHM) solutions can process clinical, financial, and operational data that help improve efficiency and patient care. The health management program is also witnessing changes in medical reimbursement due to the increasing emphasis on value-based payment models and Accountable Care Organizations (ACOs).

The COVID-19 pandemic has intensified the need for social distance among physicians and other healthcare workers, driving the need for population health management solutions and the correct and timely transmission of patient health information and claims data for patients with chronic diseases. PHM provides effective tools in this regard, including a framework for the secure transmission, sharing, and retrieval of electronic health information and claims data. For clinical and financial decision-making, these technologies enable the smooth transmission and analysis of health-related data between healthcare institutions and patients.

Furthermore, as patient numbers increase, so does the requirement for electronic medical records and electronic health record solutions to manage complicated patient data. Players in this market have also connected the electronic health record platforms with other IT solutions such as population health management and enhanced their software solutions to assist healthcare practitioners in efficiently managing COVID-19 patients. The convenience offered by value-based payment models is responsible for the increased adoption of population health solutions by ACOs.

ACOs, consisting of hospitals, clinics, and other healthcare providers, collaborate with the payers (private and public) to provide high-quality care to the patients. Private and public insurance providers have introduced various disease management programs that help in the treatment of chronic illnesses. These multidisciplinary efforts are expected to result in efficient treatment outcomes and are likely to suggest the best suitable courses of action that need to be undertaken. Successful large-scale trials in the U.S. have enabled significant advancements in disease management programs.

Most healthcare providers worldwide have insufficient infrastructure, including health professionals, patients’ data, technology, and other resources to manage healthcare issues. To manage a large population, suppliers must invest considerably in infrastructure development. The government's expanded monitoring support for healthcare IT systems, as well as the rising use of big data analytics and the need to contain expanding healthcare costs, would all fuel the expansion of the population health management industry.

Request a free sample copy or view the report summary: Population Health Management Market Report

Population Health Management Market Report Highlights

PHM software offers predictive data analytics, which can be applied for interpreting population characteristics from unstructured clinical data

The services product segment held a majority of the market share in 2021, as healthcare providers prefer in-house maintenance services

Healthcare providers held the largest market share of the end-use segment in 2021. The providers can focus effectively on patient-centric care and reducing overall costs. The large market share is attributed to the implementation of the ACA which is the Affordable Care Act for the prevention of diseases, and the adoption of IT in healthcare, this will boost the market growth and create opportunities for the service provider to effectively collect and maintain patients' data.

North America was the largest regional market in 2021 and is likely to retain its position over the forecast period, as the providers, payers, providers-payers, and accountable care organizations promote the use of PHM services

In Asia Pacific, the market is expected to witness the fastest growth in the coming years due to rising healthcare expenditure and improving healthcare infrastructure in the region

Acquisitions and business partnerships with other market players are some of the strategic initiatives undertaken by key players to strengthen their market presence

Population Health Management Market Segmentation

Grand View Research has segmented the global population health management market based on the product, end use, delivery mode, and region:

Population Health Management Product Outlook (Revenue, USD Million, 2017 - 2030)

Software

Services

Population Health Management End-use Outlook (Revenue, USD Million, 2017 - 2030)

Payers

Providers

Employer Groups

Population Health Management Delivery Mode Outlook (Revenue, USD Million, 2017 - 2030)

On-Premise

Cloud-based

Population Health Management Regional Outlook (Revenue, USD Million, 2017 - 2030)

North America

U.S.

Canada

Europe

U.K.

Germany

France

Italy

Spain

Asia Pacific

Japan

China

India

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

United Arab Emirates

List of Key Players in Population Health Management Market

Allscripts

McKesson Corporation

Cerner Corporation

Conifer Health Solutions LLC

eClinicalWorks

[marketreports-blog]

Nova one advisor recently published a research report on "U.S. Healthcare Payer Analytics Market Share, Size, Trends, Industry Analysis Report, By Analytics Type (Descriptive Analytics), By Component (Software), By Delivery Model, By Application; By Region; Segment Forecast, 2022 - 2030" in its research database.

According to recent research study, the U.S. Healthcare Payer Analytics market size & share is expected to grow at a CAGR of 22.6% between 2022 and 2030. The U.S. Healthcare Payer Analytics industry revenue of USD 3.5 Billion in 2021 is expected to grow up to USD 19.7 Billion by 2030.

[metiresearchinfo]

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Forecast to 2028

The U.S. RWE Solutions Market is expected to grow at a CAGR of 13% from 2021 to 2028 to reach $2.01 billion by 2028.Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare have been considered to have a positive impact on the U.S. RWE solutions market.

Impact of COVID-19 on the U.S. RWE Solutions Market

The key players operating in the U.S. RWE solutions market experienced an initial shrinkage due to uncertainties associated with the impact of the COVID-19 pandemic. The market shrinkage was mainly due to significant restrictions on travel in many countries, shifting resources on COVID-19 treatments in healthcare settings, and limited access to hospitals. However, after initial shrinkage, the adoption of real-world evidence (RWE) is rising to fight against the COVID-19 outbreak.

Healthcare professionals are working tirelessly on faster diagnosis, rapid response, and effective use of human resources, and ensuring medical personnel's safety. As the COVID-19 outbreak continues to take its toll on U.S. markets, real-world evidence (RWE) is the most influential emerging technology to fight against the COVID-19 outbreak. Real-world evidence is becoming an essential tool in trying to suppress COVID-19.

There is growing interest in whether non-randomized real-world evidence (RWE) can be used to supplement RCT evidence and aid in clinical decision-making but concerns about non-randomized RWE have been highlighted by a proliferation of RWE studies on medications and COVID-19 outcomes with widely varying conclusions. A systematic approach to generating information to support clinical and public health decision-making is needed. Real-world data (RWD) captured directly from patients or through medical claims or electronic medical records (EMRs) have the potential to support clinical decision-making.

                                                               Click here to : Get Free Sample Pages of this Report

Key Findings in the U.S. RWE Solutions Market Study

Datasets Generated Larger Proportion of Revenue Compared to Consulting and Analytics

The datasets segment accounted for the largest share of the U.S. RWE solutions market in 2021. The large share of this segment is primarily attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment; the growing amount of medical data generated in hospitals; increasing dependence of outcome-based studies on real-world data; and rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Market access & Reimbursement/Coverage Decisions to Dominate the Market

The market access & reimbursement/coverage decisions segment accounted for the largest share of the U.S. RWE solutions market in 2021. The large share of this segment is primarily attributed to the increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE).

Real-world data (RWD) is being increasingly considered by both industry and payers in the U.S. Payers use the data to support coverage decisions, develop guidelines and decision support tools for use in clinical practice, generate estimates of the potential population they cover that could require the treatment, and estimate potential costs and cost offsets.

Pharmaceutical & Medical Device Companies Segment Accounted for the Largest Share in the U.S. RWE solutions market

The pharmaceutical & medical device companies segment accounted for the largest share of the U.S. RWE solutions market in 2021. The large share of this segment is mainly attributed increasing importance of RWE studies in drug development & approvals, and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

The healthcare landscape continues to shift from volume to value-based care and is continuously developing. Pharmaceutical companies have been looking for new ways to provide the best treatments for patients. Real-world evidence helps understand real-life clinical practices and actual health outcomes of drugs. Pharmaceutical and biotech companies are increasingly utilizing real-world evidence for collecting real-time post-trial information about drugs, which helps healthcare providers and researchers understand the negative reactions, side effects, and medication errors related to the drugs, thereby enabling them to control the potential harm caused by the drugs.

Key Players

The report includes a competitive landscape based on extensive assessment of the key strategic developments that led market participants to adopt over the past four years . The key players profiled in the U.S. RWE solutions market report includes IQVIA HOLDINGS INC. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), Flatiron Health (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings, Inc. (U.S.), and Symphony Innovation, LLC (U.S.).

Scope of the Report

U.S. RWE Solutions Market, by Component

Datasets

Consulting and Analytics

Disparate Datasets

Integrated Datasets

EMR/EHR/Clinical Data

Claims & Billing Data

Pharmacy Data

Product/Disease Registries Data

Other Disparate Datasets

(Note – Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

U.S. RWE Solutions Market, by Application

Market Access & Reimbursement/Coverage Decisions

Drug Development & Approvals

Post Market Surveillance

Medical Device Development & Approvals

Other Applications

Oncology

Neurology

Immunology

Cardiovascular Diseases

Other Therapeutic Areas

(Note – Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases/ Other Applications include regulatory and clinical decision-making)

U.S. RWE Solutions Market, by End User

Pharmaceutical, Biotechnology, and Medical Device Companies

Healthcare Payers

Healthcare Providers

Other End Users

(Note – Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)